CA2514117A1 - Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents - Google Patents

Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents Download PDF

Info

Publication number
CA2514117A1
CA2514117A1 CA002514117A CA2514117A CA2514117A1 CA 2514117 A1 CA2514117 A1 CA 2514117A1 CA 002514117 A CA002514117 A CA 002514117A CA 2514117 A CA2514117 A CA 2514117A CA 2514117 A1 CA2514117 A1 CA 2514117A1
Authority
CA
Canada
Prior art keywords
phenylalanine
sulfonyl
substituted
dimethylcarbamyloxy
prolyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002514117A
Other languages
English (en)
French (fr)
Inventor
Steve J. Karlik
Michael A. Pleiss
Andrei W. Konradi
Francine S. Grant
Christopher M. Semko
Daren Dressen
Elizabeth Messersmith
Stephen Freedman
Ted Yednock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2514117A1 publication Critical patent/CA2514117A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CA002514117A 2003-01-24 2004-01-26 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents Abandoned CA2514117A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44217103P 2003-01-24 2003-01-24
US60/442,171 2003-01-24
US50031603P 2003-09-05 2003-09-05
US60/500,316 2003-09-05
PCT/US2004/002028 WO2004066931A2 (en) 2003-01-24 2004-01-26 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents

Publications (1)

Publication Number Publication Date
CA2514117A1 true CA2514117A1 (en) 2004-08-12

Family

ID=32829779

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002514117A Abandoned CA2514117A1 (en) 2003-01-24 2004-01-26 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
CA002514125A Abandoned CA2514125A1 (en) 2003-01-24 2004-01-26 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002514125A Abandoned CA2514125A1 (en) 2003-01-24 2004-01-26 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents

Country Status (16)

Country Link
US (2) US20050069541A1 (OSRAM)
EP (4) EP1592387A4 (OSRAM)
JP (4) JP2006516624A (OSRAM)
KR (2) KR20050114212A (OSRAM)
AU (5) AU2004207536B2 (OSRAM)
CA (2) CA2514117A1 (OSRAM)
CO (1) CO5670359A2 (OSRAM)
IL (1) IL169770A (OSRAM)
MX (2) MXPA05007823A (OSRAM)
NO (1) NO20053920L (OSRAM)
PE (1) PE20040942A1 (OSRAM)
RU (1) RU2412721C2 (OSRAM)
SK (1) SK50642005A3 (OSRAM)
TW (2) TW201311238A (OSRAM)
UY (1) UY28170A1 (OSRAM)
WO (2) WO2004066932A2 (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
EP3674322A1 (en) * 2002-02-25 2020-07-01 Biogen MA Inc. Administration of agents for the treatment of inflammation
JP2006516624A (ja) 2003-01-24 2006-07-06 エラン ファーマシューティカルズ，インコーポレイテッド 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
EP1706399A1 (en) * 2004-01-23 2006-10-04 Elan Pharmaceuticals, Inc. Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
BRPI0513143A (pt) * 2004-07-08 2008-04-29 Elan Pharm Inc antagonistas de vla-4 multivalentes compreendendo porções poliméricas
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
JP2008520717A (ja) * 2004-11-19 2008-06-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多発性硬化症についての処置
WO2006060787A2 (en) * 2004-12-03 2006-06-08 Biogen Idec Ma Inc. Delaying or preventing onset of multiple sclerosis
WO2006114115A1 (de) 2005-04-26 2006-11-02 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
US7786266B2 (en) * 2005-05-12 2010-08-31 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-DSC2 antibody
NZ563577A (en) 2005-05-20 2011-04-29 Elan Pharm Inc Imidazolone phenylalanine derivatives as VLA-4 antagonists
US20070106035A1 (en) * 2005-10-26 2007-05-10 Medivas, Llc Aromatic di-acid-containing poly (ester amide) polymers and methods of use
WO2007050583A2 (en) * 2005-10-26 2007-05-03 Medivas, Llc Aromatic di-acid-containing poly (ester amide) polymers and methods of use
US8017612B2 (en) * 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US9008378B2 (en) 2006-12-20 2015-04-14 The Board Of Trustees Of The Leland Stanford Junior University Arrangement and imaging of biological samples
WO2009029936A1 (en) * 2007-08-31 2009-03-05 Case Western Reserve University In vivo imaging of myelin
AU2009298888A1 (en) * 2008-09-23 2010-04-08 Georgetown University 1,2-benzisothiazolinone and isoindolinone derivatives
EP2419137A4 (en) * 2009-04-17 2013-01-09 Biogen Idec Inc COMPOSITIONS AND METHOD FOR TREATING ACUTE MYELOGENIC LEUKEMIA
EP2467159A1 (en) * 2009-08-20 2012-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
EA201291065A1 (ru) 2010-04-16 2013-03-29 Байоджен Айдек Ма Инк. Антитела против vla-4
EP2588112B1 (en) * 2010-06-30 2017-09-27 Victoria Link Ltd Methods and compositions for treatment of multiple sclerosis
ES2654820T3 (es) 2010-10-25 2018-02-15 Biogen Ma Inc. Métodos para determinar diferencias en la actividad de la alfa-4-integrina mediante la correlación de las diferencias en los niveles de sVCAM y/o sMAdCAM
PH12013500990A1 (en) * 2010-11-19 2022-11-23 Eisai R&D Man Co Ltd Neutralizing anti-ccl20 antibodies
AU2012296543B2 (en) 2011-08-16 2016-08-11 Georgetown University Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives
ES2943585T3 (es) 2012-02-29 2023-06-14 Takeda Pharmaceuticals Co Remielinización estimulada por IgG de nervios periféricos
TWI660972B (zh) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
AU2013329421A1 (en) * 2012-10-09 2015-04-30 Biogen Ma Inc. Combination therapies and uses for treatment of demyelinating disorders
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
EP3116911B8 (en) 2014-03-12 2019-10-23 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
WO2015136468A1 (en) * 2014-03-13 2015-09-17 Prothena Biosciences Limited Combination treatment for multiple sclerosis
KR102364840B1 (ko) 2014-11-05 2022-02-18 삼성전자주식회사 신경세포의 탈수초화와 연관된 질환을 치료하기 위한 약학적 조성물 및 그를 이용하는 방법
CA2970058A1 (en) * 2014-12-12 2016-06-16 Commonwealth Scientific And Industrial Research Organisation Dislodgement and release of hsc from the bone marrow stem cell niche using alpha9 integrin antagonists
WO2016138538A2 (en) * 2015-02-27 2016-09-01 The General Hospital Corporation Therapeutic use of integrin-binding antibodies
JP2018515424A (ja) 2015-03-10 2018-06-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗アルファｖベータ１インテグリン阻害剤及び使用方法
CN106316982B (zh) * 2015-06-30 2020-08-14 中国人民解放军军事医学科学院毒物药物研究所 噻嗪酰胺衍生物及其用途
US10947311B2 (en) * 2015-11-20 2021-03-16 The Board Of Trustees Of The Leland Stanford Junior University VCAM-1 mediated methods and compositions for treating aging-associated impairments
BR112020022249A2 (pt) * 2018-05-23 2021-02-23 Csl Behring Ag tratamento de cidp
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
US20220119383A1 (en) 2018-10-30 2022-04-21 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
CN119431230A (zh) 2019-08-14 2025-02-14 吉利德科学公司 用于抑制α4β7整合素的化合物

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
EP0330506A3 (en) 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
SU1718797A1 (ru) * 1990-01-04 1992-03-15 Ленинградский Государственный Институт Усовершенствования Врачей Им.С.М.Кирова Способ дифференциальной диагностики поражени нервных стволов
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
CA2072249C (en) 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
CA2153692C (en) 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
DK0682529T4 (da) 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
JP2001508020A (ja) * 1994-06-02 2001-06-19 シエーリング アクチエンゲゼルシヤフト 多発性硬化症治療用のｐｄｅ ｉｖ阻害剤
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
US6001809A (en) 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
CA2193508A1 (en) 1994-07-11 1996-01-25 Eugene D. Thorsett Inhibitors of leukocyte adhesion
US6027726A (en) 1994-09-30 2000-02-22 Inex Phamaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6284473B1 (en) * 1995-10-02 2001-09-04 Uab Research Foundation P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US6306384B1 (en) 1996-10-01 2001-10-23 E-L Management Corp. Skin battery cosmetic composition
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
EP1001764A4 (en) 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
EP1017382B1 (en) * 1997-05-29 2006-03-01 Merck & Co., Inc. (a New Jersey corp.) Biarylalkanoic acids as cell adhesion inhibitors
AU8823498A (en) 1997-07-31 1999-02-22 American Home Products Corporation Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
US6583139B1 (en) * 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) * 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US7030114B1 (en) * 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) * 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
CA2290747A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
EP1001975A1 (en) * 1997-07-31 2000-05-24 Elan Pharmaceuticals, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
US6489300B1 (en) * 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US6362341B1 (en) * 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6423688B1 (en) * 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
KR20010022414A (ko) * 1997-07-31 2001-03-15 진 엠. 듀발 Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제시키는4-아미노-페닐알라닌형 화합물
US6492421B1 (en) * 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en) * 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
US6436904B1 (en) * 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
EP1150997A1 (en) * 1999-01-25 2001-11-07 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
CA2361256A1 (en) * 1999-01-29 2000-08-03 James B. Rottman Method of treating demyelinating inflammatory disease using ccr1 antagonists
US6387930B1 (en) * 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
ES2335643T3 (es) 1999-12-16 2010-03-31 Biogen Idec Ma Inc. Metodos de tratamiento de lesion isquemica o hemorragica del sistema nervioso central usando antagonistas anti-integrinas alfa 4.
EP1253923A1 (en) * 2000-01-28 2002-11-06 Biogen, Inc. Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses
EP2287191B1 (en) * 2000-05-10 2016-10-12 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US6653313B2 (en) * 2000-08-10 2003-11-25 Warner-Lambert Company Llc 1,4-dihydropyridine compounds as bradykinin antagonists
AU2001292846A1 (en) * 2000-09-20 2002-04-29 Surromed, Inc. Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
EP3674322A1 (en) * 2002-02-25 2020-07-01 Biogen MA Inc. Administration of agents for the treatment of inflammation
JP2006516624A (ja) 2003-01-24 2006-07-06 エラン ファーマシューティカルズ，インコーポレイテッド 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
US9501219B2 (en) 2012-01-25 2016-11-22 Oracle International Corporation 2D line data cursor

Also Published As

Publication number Publication date
AU2004207536B2 (en) 2010-05-20
JP2006516624A (ja) 2006-07-06
EP3527228A1 (en) 2019-08-21
NO20053920L (no) 2005-10-24
US7576101B2 (en) 2009-08-18
EP1592386A4 (en) 2007-06-13
US20050215565A1 (en) 2005-09-29
US20050069541A1 (en) 2005-03-31
JP2007521249A (ja) 2007-08-02
AU2011201262A1 (en) 2011-04-07
TWI428141B (zh) 2014-03-01
EP1592386A2 (en) 2005-11-09
KR20050114212A (ko) 2005-12-05
SK50642005A3 (sk) 2006-02-02
WO2004066932A3 (en) 2006-06-01
EP1592387A4 (en) 2009-05-06
IL169770A (en) 2012-08-30
AU2004207535A1 (en) 2004-08-12
CA2514125A1 (en) 2004-08-12
AU2010212446A1 (en) 2010-09-09
EP2484381A1 (en) 2012-08-08
JP2014040458A (ja) 2014-03-06
TW200427462A (en) 2004-12-16
WO2004066932A2 (en) 2004-08-12
NO20053920D0 (no) 2005-08-23
MXPA05007843A (es) 2005-10-18
RU2005126728A (ru) 2006-01-20
EP1592387A2 (en) 2005-11-09
CO5670359A2 (es) 2006-08-31
TW201311238A (zh) 2013-03-16
AU2010212446B2 (en) 2011-03-31
WO2004066931A3 (en) 2005-12-15
KR20130100802A (ko) 2013-09-11
RU2412721C2 (ru) 2011-02-27
JP2011225577A (ja) 2011-11-10
AU2010201472A1 (en) 2010-05-06
PE20040942A1 (es) 2004-12-28
AU2004207536A1 (en) 2004-08-12
MXPA05007823A (es) 2005-10-18
WO2004066931A2 (en) 2004-08-12
UY28170A1 (es) 2004-07-30
KR101260497B1 (ko) 2013-09-12

Similar Documents

Publication Publication Date Title
US7576101B2 (en) Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
US7605166B2 (en) Methods and compositions for treating rheumatoid arthritis
CA2561164A1 (en) Steroid sparing agents and their use
CN1942161B (zh) 通过施用髓鞘再生药物用于脱髓鞘疾病和麻痹的组合物和治疗
HK40013033A (en) Composition for a treatment of demyelinating diseases and paralysis by administration of remyelinating agents

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued